These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 31088747)

  • 21. Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials.
    Shedlock DJ; Silvestri G; Weiner DB
    Nat Rev Immunol; 2009 Oct; 9(10):717-28. PubMed ID: 19859066
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.
    Pal R; Venzon D; Letvin NL; Santra S; Montefiori DC; Miller NR; Tryniszewska E; Lewis MG; VanCott TC; Hirsch V; Woodward R; Gibson A; Grace M; Dobratz E; Markham PD; Hel Z; Nacsa J; Klein M; Tartaglia J; Franchini G
    J Virol; 2002 Jan; 76(1):292-302. PubMed ID: 11739694
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunization of macaques with live simian human immunodeficiency virus (SHIV) vaccines conferred protection against AIDS induced by homologous and heterologous SHIVs and simian immunodeficiency virus.
    Kumar A; Mukherjee S; Shen J; Buch S; Li Z; Adany I; Liu Z; Zhuge W; Piatak M; Lifson J; McClure H; Narayan O
    Virology; 2002 Sep; 301(2):189-205. PubMed ID: 12359422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A clinically relevant HIV-1 subunit vaccine protects rhesus macaques from in vivo passaged simian-human immunodeficiency virus infection.
    Mooij P; van der Kolk M; Bogers WM; ten Haaft PJ; Van Der Meide P; Almond N; Stott J; Deschamps M; Labbe D; Momin P; Voss G; Von Hoegen P; Bruck C; Heeney JL
    AIDS; 1998 Mar; 12(5):F15-22. PubMed ID: 9543435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model.
    Nehete PN; Chitta S; Hossain MM; Hill L; Bernacky BJ; Baze W; Arlinghaus RB; Sastry KJ
    Vaccine; 2001 Dec; 20(5-6):813-25. PubMed ID: 11738745
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superior Efficacy of a Human Immunodeficiency Virus Vaccine Combined with Antiretroviral Prevention in Simian-Human Immunodeficiency Virus-Challenged Nonhuman Primates.
    Le Grand R; Dereuddre-Bosquet N; Dispinseri S; Gosse L; Desjardins D; Shen X; Tolazzi M; Ochsenbauer C; Saidi H; Tomaras G; Prague M; Barnett SW; Thiebaut R; Cope A; Scarlatti G; Shattock RJ
    J Virol; 2016 Jun; 90(11):5315-5328. PubMed ID: 27009957
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies.
    Silveira EL; Kasturi SP; Kovalenkov Y; Rasheed AU; Yeiser P; Jinnah ZS; Legere TH; Pulendran B; Villinger F; Wrammert J
    J Immunol Methods; 2015 Jan; 416():69-83. PubMed ID: 25445326
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection.
    Mooij P; Nieuwenhuis IG; Knoop CJ; Doms RW; Bogers WM; Ten Haaft PJ; Niphuis H; Koornstra W; Bieler K; Köstler J; Morein B; Cafaro A; Ensoli B; Wagner R; Heeney JL
    J Virol; 2004 Apr; 78(7):3333-42. PubMed ID: 15016855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Humoral immunity to HIV, SIV, and SHIV.
    Haigwood NL; Zolla-Pazner S
    AIDS; 1998; 12 Suppl A():S121-32. PubMed ID: 9632993
    [No Abstract]   [Full Text] [Related]  

  • 30. Characterization of an effective CTL response against HIV and SIV infections.
    Genescà M
    J Biomed Biotechnol; 2011; 2011():103924. PubMed ID: 21976964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Induction of HIV-specific antibody response and protection against vaginal SHIV transmission by intranasal immunization with inactivated SHIV-capturing nanospheres in macaques.
    Miyake A; Akagi T; Enose Y; Ueno M; Kawamura M; Horiuchi R; Hiraishi K; Adachi M; Serizawa T; Narayan O; Akashi M; Baba M; Hayami M
    J Med Virol; 2004 Jul; 73(3):368-77. PubMed ID: 15170630
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perpetuation of vaccine memory T cell responses against SIV/HIV.
    Lévy Y
    EMBO Mol Med; 2011 Sep; 3(9):507-9. PubMed ID: 21830302
    [No Abstract]   [Full Text] [Related]  

  • 33. Immunogenicity of attenuated vesicular stomatitis virus vectors expressing HIV type 1 Env and SIV Gag proteins: comparison of intranasal and intramuscular vaccination routes.
    Egan MA; Chong SY; Rose NF; Megati S; Lopez KJ; Schadeck EB; Johnson JE; Masood A; Piacente P; Druilhet RE; Barras PW; Hasselschwert DL; Reilly P; Mishkin EM; Montefiori DC; Lewis MG; Clarke DK; Hendry RM; Marx PA; Eldridge JH; Udem SA; Israel ZR; Rose JK
    AIDS Res Hum Retroviruses; 2004 Sep; 20(9):989-1004. PubMed ID: 15585086
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a novel rhesus macaque model with an infectious R5 simian-human immunodeficiency virus encoding HIV-1 CRF08_BC env.
    Huang L; Kusagawa S; Zeng H; Yang G; Sun B; Miura T; Yang R
    J Med Primatol; 2014 Feb; 43(1):11-21. PubMed ID: 24020838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of virus burden and chemokine expression on immunity to SHIV in nonhuman primates.
    Waterman PM; Kitabwalla M; Hatfield GS; Evans PS; Lu Y; Tikhonov I; Bryant JL; Pauza CD
    Viral Immunol; 2004; 17(4):545-57. PubMed ID: 15671751
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity and efficacy of DNA/MVA HIV vaccines in rhesus macaque models.
    Chea LS; Amara RR
    Expert Rev Vaccines; 2017 Oct; 16(10):973-985. PubMed ID: 28838267
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An SHIV DNA/MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS.
    Wang SW; Bertley FM; Kozlowski PA; Herrmann L; Manson K; Mazzara G; Piatak M; Johnson RP; Carville A; Mansfield K; Aldovini A
    AIDS Res Hum Retroviruses; 2004 Aug; 20(8):846-59. PubMed ID: 15320989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dominant induction of vaccine antigen-specific cytotoxic T lymphocyte responses after simian immunodeficiency virus challenge.
    Takahara Y; Matsuoka S; Kuwano T; Tsukamoto T; Yamamoto H; Ishii H; Nakasone T; Takeda A; Inoue M; Iida A; Hara H; Shu T; Hasegawa M; Sakawaki H; Horiike M; Miura T; Igarashi T; Naruse TK; Kimura A; Matano T
    Biochem Biophys Res Commun; 2011 May; 408(4):615-9. PubMed ID: 21531211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.
    Amara RR; Smith JM; Staprans SI; Montefiori DC; Villinger F; Altman JD; O'Neil SP; Kozyr NL; Xu Y; Wyatt LS; Earl PL; Herndon JG; McNicholl JM; McClure HM; Moss B; Robinson HL
    J Virol; 2002 Jun; 76(12):6138-46. PubMed ID: 12021347
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-cellular antibodies in sera from vaccinated macaques can induce complement-mediated virolysis of human immunodeficiency virus and simian immunodeficiency virus.
    Spear GT; Takefman DM; Sullivan BL; Landay AL; Jennings MB; Carlson JR
    Virology; 1993 Aug; 195(2):475-80. PubMed ID: 8337824
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.